In order to determine the safety of using amantadine and inosinenicotinamideriboflavinsuccinic acid in intensive treatment of victims with severe traumatic brain injury, a prospective controlled, blind, randomized study was conducted in which 54 people were included. Group I included 19 people who received standard intensive treatment. In group II (18 people) amantadine was included in the complex of intensive treatment. In group III (17 people), inosinnicotinamideriboflavinsuccinic acid was included in the complex of intensive treatment. The use of inosineicotinamideriboflavinsuccinic acid or amanta156 Scientific research of the SCO countries: synergy and integration International Conference dine (3 days after injury) in the complex intensive treatment of severe traumatic brain injury in the early periods, provided that hemodynamics and respiration are corrected, does not alter the structure and does not aggravate the manifestation of multiorgan failure